

alberico Catapano

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6029089/alberico-catapano-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

528 papers	39,508 citations	82 h-index	189 g-index
683 ext. papers	51,672 ext. citations	5.7 avg, IF	7.16 L-index

#	Paper	IF	Citations
528	Targeted proteomics improves cardiovascular risk prediction in secondary prevention.. <i>European Heart Journal</i> , 2022 ,	9.5	3
527	Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review.. <i>Cardiovascular Drugs and Therapy</i> , 2022 , 1	3.9	0
526	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. <i>Lancet, The</i> , 2022 ,	40	4
525	The zebrafish model system for dyslipidemia and atherosclerosis research: Focus on environmental/exposome factors and genetic mechanisms.. <i>Metabolism: Clinical and Experimental</i> , 2022 , 155138	12.7	2
524	The year in cardiovascular medicine 2021: dyslipidaemia.. <i>European Heart Journal</i> , 2022 ,	9.5	2
523	New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia.. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022 ,	4	2
522	Design and rationale of a nationwide screening analysis from the LIPIDOGram2015 and LIPIDOGEn2015 studies.. <i>Archives of Medical Science</i> , 2022 , 18, 604-616	2.9	3
521	Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.. <i>Journal of the American Heart Association</i> , 2022 , e023668	6	2
520	Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues.. <i>FASEB Journal</i> , 2022 , 36, e22107	0.9	3
519	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events.. <i>Annals of Medicine</i> , 2022 , 54, 1036-1046	1.5	1
518	Adherence to the Mediterranean Diet: Impact of Geographical Location of the Observations. <i>Nutrients</i> , 2022 , 14, 2040	6.7	1
517	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement. <i>Atherosclerosis</i> , 2021 , 338, 55-63	3.1	0
516	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2021 , 50, 401-411	1.9	4
515	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2021 , 1	3.6	1
514	Proteomics-Enabled Deep Learning Machine Algorithms Can Enhance Prediction of Mortality. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1621-1631	15.1	4
513	Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 79	6	3
512	Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis. <i>Journal of Clinical Lipidology</i> , 2021 ,	4.9	2

511	Recent insights into low-density lipoprotein metabolism and therapy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021 , 24, 120-126	3.8	2
510	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 1279-1289	3.9	92
509	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. <i>Journal of Internal Medicine</i> , 2021 , 290, 116-128	10.8	11
508	Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. <i>Cardiovascular Research</i> , 2021 , 117, 2069-2082	9.9	15
507	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021 , 320, 1-9	3.1	1
506	Inflammaging and neurodegenerative diseases: Role of NLRP3 inflammasome activation in brain atherosclerotic vascular disease. <i>Mechanisms of Ageing and Development</i> , 2021 , 195, 111467	5.6	3
505	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. <i>Atherosclerosis</i> , 2021 , 322, 77-81	3.1	5
504	Role of Bempedoic Acid in Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 853-864	3.9	16
503	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. <i>Cells</i> , 2021 , 10,	7.9	6
502	Global epidemiology of dyslipidaemias. <i>Nature Reviews Cardiology</i> , 2021 , 18, 689-700	14.8	32
501	Reduction of Cardio-Metabolic Risk and Body Weight through a Multiphasic Very-Low Calorie Ketogenic Diet Program in Women with Overweight/Obesity: A Study in a Real-World Setting. <i>Nutrients</i> , 2021 , 13,	6.7	7
500	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021 , 325, 99-109	3.1	22
499	HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. <i>Cells</i> , 2021 , 10,	7.9	6
498	A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. <i>Frontiers in Immunology</i> , 2021 , 12, 701275	8.4	2
497	Omega-3 for Cardiovascular Diseases: Where Do We Stand After REDUCE-IT and STRENGTH?. <i>Circulation</i> , 2021 , 144, 183-185	16.7	3
496	Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. <i>Molecular Aspects of Medicine</i> , 2021 , 77, 100918	16.7	4
495	Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years. <i>Clinical Chemistry</i> , 2021 , 67, 30-32	5.5	0
494	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. <i>Cardiovascular Research</i> , 2021 , 117, 1033-1045	9.9	4

493	Update on Lipids and Lipoproteins-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 400-401	27.4	0
492	Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis. <i>Nutrients</i> , 2021 , 13,	6.7	7
491	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	1
490	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study). <i>Nutrients</i> , 2021 , 13,	6.7	4
489	Effect of Lipids and Lipoproteins on Hematopoietic Cell Metabolism and Commitment in Atherosclerosis. <i>Immunometabolism</i> , 2021 , 3, e210014	4.1	5
488	Clinical decision support system for lipid metabolism disorders: relevance and potential. <i>Russian Journal of Cardiology</i> , 2021 , 26, 4539	1.3	
487	PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 3078-3090	9.5	8
486	Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	3
485	Lipoprotein remnants: to be or not to be. <i>European Heart Journal</i> , 2021 ,	9.5	1
484	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe [Methodology and rationale for the multinational observational SANTORINI study. <i>Atherosclerosis Plus</i> , 2021 , 43, 24-30		2
483	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021 ,	9.5	35
482	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021 , 398, 1713-1725	4.0	14
481	Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Neurology, The</i> , 2021 , 20, 795-820	24.1	229
480	Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	5
479	Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2982-3021	15.1	922
478	A pragmatic controlled trial to improve the appropriate prescription of drugs in adult outpatients: design and rationale of the EDU.RE.DRUG study. <i>Primary Health Care Research and Development</i> , 2020 , 21,	1.6	2
477	A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. <i>Atherosclerosis</i> , 2020 , 314, 33-40	3.1	12
476	New Pharmacological Approaches to Target PCSK9. <i>Current Atherosclerosis Reports</i> , 2020 , 22, 24	6	22

475	Multifactorial Activation of NLRP3 Inflammasome: Relevance for a Precision Approach to Atherosclerotic Cardiovascular Risk and Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
474	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020 , 66, 447-459	5.5	2
473	Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2020 , 160, 105060	10.2	11
472	LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. <i>Atherosclerosis</i> , 2020 , 297, 8-15	3.1	4
471	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , 2020 , 294, 46-61	3.1	49
470	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020 , 1	3.2	3
469	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>Russian Journal of Cardiology</i> , 2020 , 25, 3826	1.3	96
468	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. <i>European Journal of Preventive Cardiology</i> , 2020 ,	3.9	2
467	185-OR: Efficacy and Safety of Bempedoic Acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data from Four Phase 3 Clinical Trials. <i>Diabetes</i> , 2020 , 69, 185-OR	0.9	1
466	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2020 , 42, e35-e40	1.7	1
465	Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool. <i>Atherosclerosis Supplements</i> , 2020 , 42, e65-e71	1.7	2
464	Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. <i>Atherosclerosis Supplements</i> , 2020 , 42, e59-e64	1.7	2
463	'Diet and lifestyle' in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members. <i>Atherosclerosis Supplements</i> , 2020 , 42, e9-e14	1.7	1
462	Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies. <i>Atherosclerosis Supplements</i> , 2020 , 42, e41-e48	1.7	2
461	Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy. <i>Atherosclerosis Supplements</i> , 2020 , 42, e25-e29	1.7	
460	Prevalence Of familial hypercholesterolaemia (FH) in Italian Patients with coronary artery disease: The POSTER study. <i>Atherosclerosis</i> , 2020 , 308, 32-38	3.1	3
459	Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2020 , 42, e1-e5	1.7	0
458	Lipid Clinics Network. Rationale and design of the EAS global project. <i>Atherosclerosis Supplements</i> , 2020 , 42, e6-e8	1.7	3

457	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGram2015 study. <i>Atherosclerosis Supplements</i> , 2020 , 42, e15-e24	1.7	7
456	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020 , 42, e30-e34	1.7	2
455	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020 , 42, e49-e58	1.7	4
454	Balancing cardiovascular benefit and diabetogenic harm of therapy with statins: Real-world evidence from Italy. <i>Diabetes Research and Clinical Practice</i> , 2020 , 164, 108197	7.4	2
453	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020 , 41, 2313-2330	9.5	301
452	Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: Need for customisation strategies. <i>Pharmacological Research</i> , 2020 , 155, 104514	10.2	3
451	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. <i>JAMA Cardiology</i> , 2020 , 5, 217-229	16.2	85
450	Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects. <i>Atherosclerosis</i> , 2020 , 292, 90-98	3.1	85
449	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 58, 496-517	5.9	50
448	Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 181-205	3.9	76
447	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 649-659.e6	4.9	24
446	Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. <i>Current Atherosclerosis Reports</i> , 2020 , 22, 74	6	5
445	Lipids and Lipoproteins in 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 595-596	27.4	31
444	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020 , 5, 1124-1135	16.2	46
443	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. <i>Atherosclerosis</i> , 2020 , 312, 72-78	3.1	7
442	Impact of PCSK9 on human-IPSC derived cardiomyocyte mitochondrial function and metabolism. <i>Atherosclerosis</i> , 2020 , 315, e86	3.1	
441	Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials. <i>Atherosclerosis</i> , 2020 , 315, e12-e13	3.1	4
440	The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. <i>Circulation</i> , 2020 , 142, 827-837	16.7	16

439	P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. <i>Cancer Research</i> , 2020 , 80, 3906-3919	16	
438	Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
437	Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1477-1489	5.4	1
436	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <i>Journal of the American Heart Association</i> , 2020 , 9, e018189	6	2
435	Bempedoic Acid and Glycemic Control: A Pooled Analysis of 4 Phase 3 Clinical Trials. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 577-579	4.9	2
434	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. <i>European Heart Journal</i> , 2020 , 41, 3998-4007	9.5	26
433	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 234-243	3.9	5
432	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 50-67	18.1	48
431	Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. <i>European Heart Journal</i> , 2020 , 41, 2487-2497	9.5	25
430	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 593-603	3.9	107
429	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020 , 41, 111-188	9.5	2236
428	Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study. <i>Atherosclerosis</i> , 2020 , 301, 1-7	3.1	2
427	Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. <i>JAMA Cardiology</i> , 2019 , 4, 1287-1295	16.2	121
426	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019 , 115, 510-518	9.9	41
425	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019 , 39, e1-e8	1.7	18
424	Understanding the Patient Perception of Statin Experience: A Qualitative Study. <i>Advances in Therapy</i> , 2019 , 36, 2723-2743	4.1	4
423	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019 , 290, 140-205	3.1	259
422	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1381-1391	27.4	79

421	Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 364-373	27.4	263
420	Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. <i>Stroke</i> , 2019 , 50, 1758-1765	6.7	12
419	Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk 2019 , 1, 100001		3
418	Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease 2019 , 1, 100002		2
417	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019 , 286, 40-45	3.1	6
416	Lifestyle interventions and nutraceuticals: Guideline-based approach to cardiovascular disease prevention 2019 , 1, 100003		2
415	Cholesterol metabolism, pancreatic β cell function and diabetes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 2149-2156	6.9	30
414	The Interconnection Between Immuno-Metabolism, Diabetes, and CKD. <i>Current Diabetes Reports</i> , 2019 , 19, 21	5.6	15
413	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. <i>Frontiers in Immunology</i> , 2019 , 10, 571	8.4	22
412	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. <i>New England Journal of Medicine</i> , 2019 , 380, 1022-1032	59.2	265
411	Mendelian Randomization Study of and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 1033-1042	59.2	116
410	Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. <i>Cardiovascular Research</i> , 2019 , 115, 1861-1872	9.9	15
409	Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. <i>Pharmacological Research</i> , 2019 , 143, 143-150	10.2	18
408	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. <i>European Heart Journal</i> , 2019 , 40, 357-368	9.5	64
407	Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients. <i>Pharmacological Research</i> , 2019 , 147, 104362	10.2	3
406	Biological Consequences of Dysfunctional HDL. <i>Current Medicinal Chemistry</i> , 2019 , 26, 1644-1664	4.3	34
405	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. <i>Current Opinion in Lipidology</i> , 2019 , 30, 462-469	4.4	13
404	Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine. <i>European Heart Journal</i> , 2019 , 40, 2825-2830	9.5	2

403	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019 , 280, 109-117	3.1	28
402	Lipid Lowering and Incidence of Cataract, a Role for Fibrates. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 318-319	6.1	1
401	Zc3h10 is a novel mitochondrial regulator. <i>EMBO Reports</i> , 2018 , 19,	6.5	15
400	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. <i>Atherosclerosis</i> , 2018 , 271, 120-127	3.1	22
399	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2018 , 20, 12	6	46
398	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. <i>Pharmacological Research</i> , 2018 , 130, 1-11	10.2	17
397	Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets. <i>Nature Reviews Cardiology</i> , 2018 , 15, 75-76	14.8	1
396	Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. <i>International Journal of Cardiology</i> , 2018 , 252, 193-198	3.2	25
395	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 119-127	6.4	11
394	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018 , 39, 2526-2539	9.5	156
393	Proprotein Convertase Subtilisin Kexin 9 Inhibitors. <i>Cardiology Clinics</i> , 2018 , 36, 241-256	2.5	4
392	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018 , 39, 2600-2601	9.5	9
391	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018 , 39, 1131-1143	9.5	132
390	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. <i>European Heart Journal</i> , 2018 , 39, 3521-3527	9.5	34
389	Disease trends over time and CD4CCR5 T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018 , 28, 53-63	4.5	19
388	Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation. <i>European Journal of Internal Medicine</i> , 2018 , 47, 25-31	3.9	10
387	Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1141-1156	15.1	126
386	Use of proton pump inhibitors and risk of ischemic events in the general population. <i>Atherosclerosis</i> , 2018 , 277, 123-129	3.1	12

385	Epidemiology of cardiovascular risk factors in two population-based studies. <i>Atherosclerosis Supplements</i> , 2018 , 35, e14-e20	1.7	5
384	Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. <i>Nature Communications</i> , 2018 , 9, 3083	17.4	56
383	PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?. <i>European Heart Journal</i> , 2018 , 39, 2586-2588	9.5	8
382	High density lipoprotein cholesterol and cancer: Marker or causative?. <i>Progress in Lipid Research</i> , 2018 , 71, 54-69	14.3	44
381	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. <i>European Heart Journal</i> , 2018 , 39, 2540-2545	9.5	75
380	Reprint of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2980-2995	15.1	9
379	Familial Hypercholesterolemia 2018 , 285-297		
378	Familial hypercholesterolemia treatments: Guidelines and new therapies. <i>Atherosclerosis</i> , 2018 , 277, 483-492	3.1	72
377	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018 , 277, 234-255	3.1	93
376	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018 , 277, 413-418	3.1	35
375	A mendelian randomization study comparing the effect of low-density lipoproteins and triglyceride-rich very low-density lipoproteins on the risk of coronary heart disease. <i>Atherosclerosis</i> , 2018 , 275, e78-e79	3.1	2
374	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018 , 39, 3641-3653	9.5	41
373	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018 , 64, 1006-1033	5.5	124
372	Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration. <i>PLoS ONE</i> , 2018 , 13, e0191172	3.7	31
371	Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017 , 27, 379-395	4.5	44
370	Guía ESC/EAS 2016 sobre el tratamiento de las dislipemias. <i>Revista Espanola De Cardiologia</i> , 2017 , 70, 115.e1-115.e64	1.5	22
369	Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4 T Cell Differentiation via PI3K p110/Akt-Mediated Signals. <i>Cell Metabolism</i> , 2017 , 25, 593-609	24.6	82
368	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017 , 38, 2459-2472	9.5	1267

367	Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground?. <i>Current Cardiology Reports</i> , 2017 , 19, 49	4.2	2
366	Practical aspects in the management of statin-associated muscle symptoms (SAMS). <i>Atherosclerosis Supplements</i> , 2017 , 26, 45-55	1.7	12
365	Pitavastatin and HDL: Effects on plasma levels and function(s). <i>Atherosclerosis Supplements</i> , 2017 , 27, e1-e9	1.7	13
364	Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 187-195	3.9	15
363	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. <i>British Journal of Pharmacology</i> , 2017 , 174, 3973-3985	8.6	80
362	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2017 , 106, 55-67	5.8	34
361	Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. <i>Scientific Reports</i> , 2017 , 7, 45788	4.9	10
360	Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017 , 27, 396-406	4.5	68
359	Antidrug Antibodies in Patients Treated with Alirocumab. <i>New England Journal of Medicine</i> , 2017 , 376, 1589-90	59.2	59
358	Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?. <i>Molecular Therapy</i> , 2017 , 25, 2435-2437	11.7	1
357	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017 , 29, 11-16	1.7	38
356	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017 , 29, 17-24	1.7	45
355	Detection of familial hypercholesterolemia in patients from a general practice database. <i>Atherosclerosis Supplements</i> , 2017 , 29, 25-30	1.7	14
354	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. <i>Vascular Health and Risk Management</i> , 2017 , 13, 343-351	4.4	11
353	Current guidelines on prevention with a focus on dyslipidemias. <i>Cardiovascular Diagnosis and Therapy</i> , 2017 , 7, S4-S10	2.6	12
352	Advances in Hypercholesterolemia 2017 , 663-693		1
351	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017 , 38, 2245-2255	9.5	105
350	miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. <i>Cardiovascular Research</i> , 2017 , 113, 1627-1638	9.9	49

349	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017 , 28, 458-464	4.4	2
348	Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort. <i>Diabetes Research and Clinical Practice</i> , 2017 , 133, 60-68	7.4	12
347	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. <i>Circulation</i> , 2017 , 136, 1878-1891	16.7	92
346	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 419-431	3.9	30
345	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1870-1877	3.9	33
344	Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. <i>Atherosclerosis</i> , 2017 , 263, e262-e263	3.1	4
343	Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. <i>Immunity</i> , 2017 , 47, 875-889	3.3	109
342	Automatic identification of variables in epidemiological datasets using logic regression. <i>BMC Medical Informatics and Decision Making</i> , 2017 , 17, 40	3.6	1
341	Corrigendum to "Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database" [Diabetes Res. Clin. Pract. 108 (2) (2015) 243-249]. <i>Diabetes Research and Clinical Practice</i> , 2017 , 125, 68	7.4	
340	Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?. <i>Drug Discovery Today</i> , 2017 , 22, 85-96	8.8	48
339	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 947-956	27.4	169
338	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1290-1301	15.1	133
337	2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS. <i>Russian Journal of Cardiology</i> , 2017 , 7-77	1.3	11
336	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. <i>European Heart Journal Supplements</i> , 2017 , 19, D3-D54	1.5	11
335	World Heart Federation Cholesterol Roadmap. <i>Global Heart</i> , 2017 , 12, 179-197.e5	2.9	15
334	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016 , 37, 2999-3058	9.3	1781
333	Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events. <i>International Journal of Cardiology</i> , 2016 , 223, 43-45	3.2	2
332	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>Atherosclerosis</i> , 2016 , 232, 207-274	3.1	341

331	Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016 , 252, 1-8	3.1	20
330	Drug treatment and adherence of subjects . <i>Atherosclerosis</i> , 2016 , 254, 172-178	3.1	6
329	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016 , 6, 30060	4.9	21
328	Statin use and risk of cataract: A nested case-control study within a healthcare database. <i>Atherosclerosis</i> , 2016 , 251, 153-158	3.1	15
327	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 850-61	18.1	215
326	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited	3.9	445
325	Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 194-205	3.9	60
324	Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. <i>Atherosclerosis</i> , 2016 , 245, 111-7	3.1	43
323	Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin?. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1165-73	3.9	22
322	Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 141-53	4.5	28
321	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016 , 39, 137-44	3.3	25
320	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. <i>Atherosclerosis</i> , 2016 , 246, 208-13	3.1	61
319	Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases. <i>Current Medicinal Chemistry</i> , 2016 , 23, 983-99	4.3	17
318	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016 , 11, e0162473	3.7	34
317	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 2144-2153	59.2	418
316	SAT0302 Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 777.2-777	2.4	
315	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016 , 22, 1-32	1.7	60
314	A simple informative intervention in primary care increases statin adherence. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 227-34	2.8	5

313	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular	9.5	3919
312	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016 , 18, C2-C12	1.5	56
311	Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 1182-90	6.9	27
310	Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy. <i>Atherosclerosis Supplements</i> , 2016 , 21, 1-8	1.7	12
309	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>Atherosclerosis</i> , 2016 , 253, 281-344	3.1	519
308	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016 , 118, 1812-1820	3	4
307	Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2016 , 69, 939.e1-939.e87	1.5	10
306	PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. <i>Atherosclerosis</i> , 2016 , 253, 214-224	3.1	53
305	Reply to: "Statins probably do not cause cataracts". <i>Atherosclerosis</i> , 2016 , 254, 311-312	3.1	
304	Circulating CD14+ and CD14CD16- classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. <i>Atherosclerosis</i> , 2016 , 255, 171-178	3.1	24
303	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. <i>Cardiovascular Research</i> , 2016 , 112, 429-42	9.9	83
302	Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration. <i>Diabetes Care</i> , 2015 , 38, 1921-9	14.6	52
301	IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease. <i>Atherosclerosis</i> , 2015 , 241, 498-501	3.1	21
300	Statin intolerance: diagnosis and remedies. <i>Current Cardiology Reports</i> , 2015 , 17, 27	4.2	28
299	Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 2129-37	4.4	10
298	Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies. <i>Cancer Medicine</i> , 2015 , 4, 770-80	4.8	23
297	Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database. <i>Diabetes Research and Clinical Practice</i> , 2015 , 108, 243-9	7.4	5
296	Apolipoprotein C-III: From Pathophysiology to Pharmacology. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 675-687	13.2	110

295	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015 , 36, 2425-37	9.5	430
294	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015 , 243, 257-9	3.1	123
293	Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. <i>Atherosclerosis</i> , 2015 , 243, 449-61	3.1	176
292	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015 , 19, 1-12	1.7	50
291	Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates BCAR1 and Suggests a Causal Variant. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 696-706		12
290	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 186-97	7	19
289	IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population. <i>PLoS ONE</i> , 2015 , 10, e0122414	3.7	9
288	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. <i>Journal of Experimental Medicine</i> , 2015 , 212, 905-25	16.6	86
287	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015 , 36, 1012-22	9.5	770
286	Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 689-99	9.4	133
285	Think Again About Cholesterol Survey. <i>Atherosclerosis Supplements</i> , 2015 , 20, 1-5	1.7	5
284	Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population. <i>Journal of Internal Medicine</i> , 2015 , 277, 478-87	10.8	43
283	New insights on ezetimibe. Introduction. <i>Atherosclerosis Supplements</i> , 2015 , 17, 1	1.7	
282	Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. <i>Atherosclerosis</i> , 2015 , 239, 209-17	3.1	15
281	HDL in infectious diseases and sepsis. <i>Handbook of Experimental Pharmacology</i> , 2015 , 224, 483-508	3.2	99
280	Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia? 2015 , 87-97		1
279	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. <i>Journal of Cell Biology</i> , 2015 , 209, 209401A93	7.3	
278	15-lipoxygenase-mediated modification of HDL3 impairs eNOS activation in human endothelial cells. <i>Lipids</i> , 2014 , 49, 317-26	1.6	7

277	Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States. <i>Contemporary Diabetes</i> , 2014 , 125-139	0	1
276	Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). <i>Atherosclerosis</i> , 2014 , 233, 508-509	3.1	2
275	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014 , 35, 960-8	9.5	222
274	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014 , 232, 346-60	3.1	330
273	Statins and periodontal inflammation: a pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?. <i>Atherosclerosis</i> , 2014 , 234, 381-2	3.1	2
272	Statins and skeletal muscles toxicity: from clinical trials to everyday practice. <i>Pharmacological Research</i> , 2014 , 88, 107-13	10.2	38
271	Combination therapy in dyslipidemia: where are we now?. <i>Atherosclerosis</i> , 2014 , 237, 319-35	3.1	34
270	Targeting PCSK9 for hypercholesterolemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2014 , 54, 273-93	17.9	71
269	Novel concepts in HDL pharmacology. <i>Cardiovascular Research</i> , 2014 , 103, 423-8	9.9	22
268	HDL: to treat or not to treat?. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 429	6	11
267	Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. <i>European Heart Journal</i> , 2014 , 35, 1996-2000	9.5	25
266	Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. <i>European Journal of Internal Medicine</i> , 2014 , 25, 745-50	3.9	31
265	Management of homozygous familial hypercholesterolaemia--unmet needs, updated recommendations, and clinical experience with the MTP inhibitor, lomitapide. Concluding comments. <i>Atherosclerosis Supplements</i> , 2014 , 15, 52	1.7	
264	Statins and the risk of diabetes: evidence from a large population-based cohort study. <i>Diabetes Care</i> , 2014 , 37, 2225-32	14.6	72
263	Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 518-23	4.5	26
262	Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 10-7	4.5	21
261	Statins decrease thrombin generation in patients with hypercholesterolemia. <i>European Journal of Internal Medicine</i> , 2014 , 25, 449-51	3.9	12
260	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 655-66	18.1	357

259	PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. <i>Vascular Pharmacology</i> , 2014 , 62, 103-11	5.9	27
258	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 751-9	4.5	34
257	MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 796-802	7	77
256	Medication persistence and the use of generic and brand-name blood pressure-lowering agents. <i>Journal of Hypertension</i> , 2014 , 32, 1146-53; discussion 1153	1.9	22
255	Postprandial lipemia as a cardiometabolic risk factor. <i>Current Medical Research and Opinion</i> , 2014 , 30, 1489-503	2.5	75
254	HDL in innate and adaptive immunity. <i>Cardiovascular Research</i> , 2014 , 103, 372-83	9.9	144
253	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014 , 35, 2146-57	9.5	614
252	The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. <i>Cell Metabolism</i> , 2014 , 20, 787-798	24.6	72
251	High-potency statins increase the risk of acute kidney injury: evidence from a large population-based study. <i>Atherosclerosis</i> , 2014 , 234, 224-9	3.1	15
250	Corrigendum to [Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials [Atheroscler Suppl 14 (2) (2013) 243-51]. <i>Atherosclerosis</i> , 2014 , 233, 122	3.1	3
249	The CD1d-natural killer T cell axis in atherosclerosis. <i>Journal of Innate Immunity</i> , 2014 , 6, 3-12	6.9	15
248	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 341-6	2.8	21
247	Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. <i>Atherosclerosis Supplements</i> , 2013 , 14, 237-42	1.7	21
246	Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. <i>Atherosclerosis Supplements</i> , 2013 , 14, 243-51	1.7	109
245	Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. <i>International Journal of Cardiology</i> , 2013 , 170, S16-20	3.2	26
244	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. <i>European Heart Journal</i> , 2013 , 34, 1783-9	9.5	72
243	Abdominal visceral fat measurement using dual-energy X-ray: association with cardiometabolic risk factors. <i>Obesity</i> , 2013 , 21, 1798-802	8	39
242	The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. <i>Atherosclerosis</i> , 2013 , 228, 18-28	3.1	102

241	Long-term use of statins reduces the risk of hospitalization for dementia. <i>Atherosclerosis</i> , 2013 , 230, 171-6	3.1	32
240	Different patterns characterize Omega 6 and Omega 3 long chain polyunsaturated fatty acid levels in blood from Italian infants, children, adults and elderly. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013 , 89, 215-20	2.8	21
239	C-reactive protein distribution and correlation with traditional cardiovascular risk factors in the Italian population. <i>European Journal of Internal Medicine</i> , 2013 , 24, 161-6	3.9	3
238	Prevalence of classical CD14++/CD16- but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia. <i>International Journal of Cardiology</i> , 2013 , 168, 2886-9	3.2	14
237	High-density lipoprotein subfractions--what the clinicians need to know. <i>Cardiology</i> , 2013 , 124, 116-25	1.6	81
236	Gene silencing approaches for the management of dyslipidaemia. <i>Trends in Pharmacological Sciences</i> , 2013 , 34, 198-205	13.2	25
235	MicroRNAs and lipoproteins: a connection beyond atherosclerosis?. <i>Atherosclerosis</i> , 2013 , 227, 209-15	3.1	31
234	Identification of seven loci affecting mean telomere length and their association with disease. <i>Nature Genetics</i> , 2013 , 45, 422-7, 427e1-2	36.3	624
233	Moderate alcohol use and health: a consensus document. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013 , 23, 487-504	4.5	100
232	-374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease. <i>PLoS ONE</i> , 2013 , 8, e60089	3.7	10
231	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013 , 34, 3478-90a	9.5	1551
230	LOX-1, OxLDL, and atherosclerosis. <i>Mediators of Inflammation</i> , 2013 , 2013, 152786	4.3	405
229	Soluble lectin-like oxidized low density lipoprotein receptor-1 as a biochemical marker for atherosclerosis-related diseases. <i>Disease Markers</i> , 2013 , 35, 413-8	3.2	48
228	Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. <i>Mediators of Inflammation</i> , 2013 , 2013, 725102	4.3	67
227	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. <i>Clinical Lipidology</i> , 2013 , 8, 13-41		21
226	Statins and primary liver cancer: a meta-analysis of observational studies. <i>European Journal of Cancer Prevention</i> , 2013 , 22, 229-34	2	58
225	High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. <i>Journal of Internal Medicine</i> , 2013 , 274, 252-62	10.8	57
224	Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis. <i>PLoS ONE</i> , 2013 , 8, e53808	3.7	21

223	Prevalence of the prescription of potentially interacting drugs. <i>PLoS ONE</i> , 2013 , 8, e78827	3.7	29
222	Lower rate of cardiovascular complications in patients on bolus insulin analogues: a retrospective population-based cohort study. <i>PLoS ONE</i> , 2013 , 8, e79762	3.7	6
221	Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3841-57	3.3	22
220	Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 893-900	6.7	39
219	Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. <i>Lancet, The</i> , 2012 , 379, 2053-62	4.0	421
218	Emerging role of high density lipoproteins as a player in the immune system. <i>Atherosclerosis</i> , 2012 , 220, 11-21	3.1	133
217	Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. <i>Atherosclerosis</i> , 2012 , 220, 381-6	3.1	161
216	Leonurine: a new comer in the natural compounds affecting atherosclerosis. <i>Atherosclerosis</i> , 2012 , 224, 37-8	3.1	8
215	HDL and adaptive immunity: a tale of lipid rafts. <i>Atherosclerosis</i> , 2012 , 225, 34-5	3.1	17
214	How many patients need statin treatment in a low-cardiovascular-risk country? Low-density lipoprotein-cholesterol target and distance from target distribution in an Italian cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012 , 22, 327-36	4.5	4
213	Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012 , 1822, 927-35	6.9	7
212	Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2012 , 428, 230-3	3.4	16
211	Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population. <i>PLoS ONE</i> , 2012 , 7, e31086	3.7	18
210	Adherence to lipid-lowering treatment: the patient perspective. <i>Patient Preference and Adherence</i> , 2012 , 6, 805-14	2.4	31
209	Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. <i>Oncologist</i> , 2012 , 17, 813-22	5.7	201
208	LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2012 , 1, e58	10.7	10
207	Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. <i>Journal of the American Heart Association</i> , 2012 , 1, 27-41	6	96
206	Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. <i>Current Vascular Pharmacology</i> , 2012 , 10, 257-67	3.3	32

205	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. <i>Journal of Hypertension</i> , 2012 , 30, 1056-64	1.9	63
204	MicroRNA 143-145 deficiency impairs vascular function. <i>International Journal of Immunopathology and Pharmacology</i> , 2012 , 25, 467-74	3	26
203	Pitavastatin: a different pharmacological profile. <i>Clinical Lipidology</i> , 2012 , 7, 3-9		9
202	Association between the Adherence to AHA Step 1 Nutrition Criteria and the Cardiometabolic Outcome in the General Population a Two Year Follow-Up Study. <i>Food and Nutrition Sciences (Print)</i> , 2012 , 03, 274-280	0.4	1
201	Risk factors distribution and cardiovascular disease prevalence in the Italian population: The CHECK study. <i>Open Journal of Epidemiology</i> , 2012 , 02, 90-100	0.2	3
200	Pentraxins and Atherosclerosis 2012 , 219-237		
199	High density lipoproteins and atherosclerosis: emerging aspects. <i>Journal of Geriatric Cardiology</i> , 2012 , 9, 401-7	1.7	16
198	Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study. <i>Pharmacological Research</i> , 2011 , 64, 393-6	10.2	5
197	Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011 , 21, 835-43	4.5	79
196	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011 , 32, 1769-818	9.5	2020
195	Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. <i>Atherosclerosis</i> , 2011 , 214, 331-7	3.1	32
194	Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. <i>Atherosclerosis</i> , 2011 , 217, 479-85	3.1	20
193	The new joint EAS/ESC guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011 , 217, 1	3.1	57
192	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>Atherosclerosis</i> , 2011 , 217 Suppl 1, S1-44	3.1	152
191	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>Atherosclerosis</i> , 2011 , 217, 3-46	3.1	459
190	HDLs, immunity, and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2011 , 22, 410-6	4.4	35
189	Endothelin-1 does not impair insulin-induced angiogenesis in vitro. <i>International Journal of Molecular Medicine</i> , 2011 , 28, 443-8	4.4	1
188	Novel biotinylated bile acid amphiphiles: micellar aggregates formation and interaction with hepatocytes. <i>Organic and Biomolecular Chemistry</i> , 2011 , 9, 2899-905	3.9	

187	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011 , 32, 1345-61	9.5	793
186	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010 , 31, 2844-53	9.5	1100
185	Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 1832-41	9.4	110
184	Update on the efficacy and safety of combination ezetimibe plus statin therapy. <i>Clinical Lipidology</i> , 2010 , 5, 655-684		28
183	Barriers to cardiovascular disease risk scoring and primary prevention in Europe. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010 , 103, 727-39	2.7	63
182	Dual effect of hypochlorite in the modification of high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 403, 447-51	3.4	9
181	Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010 , 20, 56-63	4.5	25
180	Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project. <i>American Heart Journal</i> , 2010 , 159, 730-736	4.9	32
179	Pitavastatin - pharmacological profile from early phase studies. <i>Atherosclerosis Supplements</i> , 2010 , 11, 3-7	1.7	30
178	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. <i>Atherosclerosis</i> , 2010 , 208, 177-82	3.1	67
177	Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. <i>Atherosclerosis</i> , 2010 , 210, 78-87	3.1	40
176	The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits tumor necrosis factor alpha and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. <i>Atherosclerosis</i> , 2010 , 212, 100-6	3.1	33
175	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. <i>Current Opinion in Lipidology</i> , 2010 , 21, 492-8	4.4	77
174	Lecithin:cholesterol acyltransferase and vascular disease. <i>Clinical Lipidology</i> , 2010 , 5, 13-15		
173	Blood pressure and antihypertensive therapy according to the global cardiovascular risk level in Italy: the CHECK Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 562-8		4
172	The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. <i>Trends in Cardiovascular Medicine</i> , 2010 , 20, 35-40	6.9	113
171	Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. <i>Clinical Therapeutics</i> , 2010 , 32, 300-10	3.5	64
170	From endothelial dysfunction to atherosclerosis. <i>Autoimmunity Reviews</i> , 2010 , 9, 830-4	13.6	307

169	Perspectives on low-density lipoprotein cholesterol goal achievement. <i>Current Medical Research and Opinion</i> , 2009 , 25, 431-47	2.5	34
168	Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. <i>Circulation</i> , 2009 , 120, 699-708	16.7	225
167	Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009 , 19, 129-34	4.5	85
166	Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass. <i>Metabolism: Clinical and Experimental</i> , 2009 , 58, 1270-6	12.7	75
165	Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. <i>Metabolic Syndrome and Related Disorders</i> , 2009 , 7, 601-10	2.6	8
164	Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. <i>Atherosclerosis</i> , 2009 , 206, 556-62	3.1	57
163	Bridging science and health policy in cardiovascular disease: focus on lipid management: A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention--Health Policy, in Venice, Italy, on 25 October, 2008. <i>Atherosclerosis Supplements</i> , 2009 , 10, 3-21	1.7	9
162	Cholesterol Absorption Inhibitors 2009 , 288-297		
161	Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 91-105	4.9	17
160	Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 436-46	4.9	12
159	Carotid artery intima-media thickness in nonalcoholic fatty liver disease. <i>American Journal of Medicine</i> , 2008 , 121, 72-8	2.4	164
158	Non-pharmacological control of plasma cholesterol levels. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008 , 18, S1-16	4.5	40
157	Side effects of anabolic androgenic steroids abuse. <i>International Journal of Sports Medicine</i> , 2008 , 29, 679-87	3.6	76
156	The 15-lipoxygenase-modified high density lipoproteins 3 fail to inhibit the TNF-alpha-induced inflammatory response in human endothelial cells. <i>Journal of Immunology</i> , 2008 , 181, 2821-30	5.3	21
155	Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, 925-31	9.4	122
154	Combination therapy in cholesterol reduction: focus on ezetimibe and statins. <i>Vascular Health and Risk Management</i> , 2008 , 4, 267-78	4.4	17
153	Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2009-26	2.5	125
152	Inhibition of synthesis and absorption of cholesterol: A new option in managing hypercholesterolemia. <i>International Congress Series</i> , 2007 , 1303, 121-128		1

151	ASSET (Age/Sex Standardised Estimates of Treatment): a research model to improve the governance of prescribing funds in Italy. <i>PLoS ONE</i> , 2007 , 2, e592	3.7	8
150	Monitoring statin safety in primary care. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 652-7	2.6	7
149	Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. <i>Journal of Internal Medicine</i> , 2007 , 262, 104-12	10.8	52
148	The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. <i>Fundamental and Clinical Pharmacology</i> , 2007 , 21 Suppl 2, 21-6	3.1	6
147	Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux. <i>Cardiovascular Research</i> , 2007 , 75, 566-74	9.9	15
146	Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 3292-7	4.3	14
145	Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. <i>Stroke</i> , 2007 , 38, 2844-6	6.7	142
144	Plasma resistin levels correlate with determinants of the metabolic syndrome. <i>European Journal of Endocrinology</i> , 2007 , 156, 279-84	6.5	151
143	Triglyceride-rich lipoproteins from normotriglyceridemic subjects and hyperlipidemic patients differently affect endothelial cell activation and gene expression patterns. <i>Circulation Research</i> , 2007 , 100, e81	15.7	7
142	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007 , 14, 340-345		
141	Triglyceride-Rich Lipoproteins And Endothelial Dysfunction: Molecular Mechanisms And Gene Expression Studies. <i>Future Lipidology</i> , 2007 , 2, 119-122		
140	ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 361, 543-8	3.4	3
139	Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. <i>Atherosclerosis</i> , 2007 , 191, 265-71	3.1	125
138	Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. <i>Atherosclerosis</i> , 2007 , 193, 321-7	3.1	105
137	Molecular Mechanisms Responsible for the Anti-Inflammatory and Protective Effect of High-Density Lipoprotein on the Endothelium. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 21-31	2.9	1
136	Genetic Polymorphisms in an Aged Population. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 99-101	2.9	0
135	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007 , 14, 340-5		0
134	In human endothelial cells amino acids inhibit insulin-induced Akt and ERK1/2 phosphorylation by an mTOR-dependent mechanism. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 47, 643-9	3.1	11

133	Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 546-54	5.6	122
132	Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: a pilot study. <i>Blood Purification</i> , 2006 , 24, 369-76	3.1	34
131	Effects of fractalkine receptor variants on common carotid artery intima-media thickness. <i>Stroke</i> , 2006 , 37, 1558-61	6.7	43
130	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. <i>Current Medical Research and Opinion</i> , 2006 , 22, 2041-53	2.5	91
129	Synthesis and biological evaluation of azido- and aziridino-hydroxyl-beta-lactams through stereo- and regioselective epoxide ring opening. <i>Journal of Organic Chemistry</i> , 2006 , 71, 9229-32	4.2	13
128	15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006 , 1761, 292-300	5	29
127	Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: Molecular mechanisms and gene expression studies. <i>Journal of Molecular and Cellular Cardiology</i> , 2006 , 40, 484-94	5.8	45
126	Modified HDL: biological and physiopathological consequences. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006 , 16, 371-86	4.5	63
125	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2006 , 18, 209	4.4	4
124	HDL and endothelial function: from molecular mechanisms to clinical observations. <i>Future Lipidology</i> , 2006 , 1, 343-355		2
123	Secondary prevention of myocardial infarction: a survey in primary care. <i>Journal of Cardiovascular Medicine</i> , 2006 , 7, 422-6	1.9	1
122	In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. <i>International Journal of Molecular Medicine</i> , 2006 , 17, 203-8	4.4	27
121	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2006 , 18, 209-13	4.4	8
120	Global cardiovascular risk : the role of plasma lipids. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005 , 12, 125-33	2.9	
119	Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1123-30	2.5	31
118	Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. <i>Journal of Internal Medicine</i> , 2005 , 258, 21-7	10.8	66
117	Acute effect of high-fat meal on endothelial function in moderately dyslipidemic subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 406-10	9.4	62
116	High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. <i>Circulation</i> , 2005 , 111, 2805-11	16.7	76

115	Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 411-7	9.4	154
114	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005 , 12, 159-63		1
113	Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. <i>Vascular Health and Risk Management</i> , 2005 , 1, 119-29	4.4	49
112	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005 , 12, 159-163		2
111	Lipoprotein remnants and endothelial dysfunction in the postprandial phase. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2946-50	5.6	61
110	Native LDL and oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF-kappaB, CRE dependent pathway and affect PGE2 synthesis. <i>International Journal of Molecular Medicine</i> , 2004 , 14, 353-9	4.4	11
109	HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 871-7	9.4	85
108	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. <i>British Journal of Haematology</i> , 2004 , 127, 97-104	4.5	47
107	Triglycerides rich lipoproteins and atherosclerosis: in vitro and in vivo studies. <i>International Congress Series</i> , 2004 , 1262, 507-510		1
106	High-density lipoprotein subfraction 3 decreases ADAMTS-1 expression induced by lipopolysaccharide and tumor necrosis factor-alpha in human endothelial cells. <i>Matrix Biology</i> , 2004 , 22, 557-60	11.4	29
105	Lipid lowering activity of drugs affecting cholesterol absorption. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004 , 14, 42-51	4.5	11
104	Effects of an automated electronic reminder in changing the antiplatelet drug-prescribing behavior among Italian general practitioners in diabetic patients: an intervention trial. <i>Diabetes Care</i> , 2003 , 26, 1497-500	14.6	76
103	Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. <i>Cardiovascular Research</i> , 2003 , 59, 169-80	9.9	50
102	Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2003 , 12, 73	4.4	1
101	. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003 , 10, 181-189		15
100	Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy. <i>Annals of Neurology</i> , 2003 , 53, 807-10	9.4	27
99	Statins and oxidative stress during atherogenesis. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003 , 10, 181-9		5
98	Heart Protection Study. <i>Lancet, The</i> , 2003 , 361, 528; author reply 529-30	40	3

97	Effect of a standardized grape seed extract on low-density lipoprotein susceptibility to oxidation in heavy smokers. <i>Metabolism: Clinical and Experimental</i> , 2003 , 52, 1250-7	12.7	82
96	Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2003 , 12, 73-8	4.4	13
95	Novel statins: pharmacological and clinical results. <i>Cardiovascular Drugs and Therapy</i> , 2002 , 16, 251-7	3.9	26
94	5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 857-64	4.3	16
93	Epitope mapping analysis of apolipoprotein B-100 using a surface plasmon resonance-based biosensor. <i>Biosensors and Bioelectronics</i> , 2001 , 16, 963-9	11.8	11
92	Overexpression of inducible heat shock protein 70 in Cos-1 cells fails to protect from cytotoxicity of oxidized ldl. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001 , 21, 348-54	9.4	17
91	Ezetimibe: a selective inhibitor of cholesterol absorption. <i>European Heart Journal Supplements</i> , 2001 , 3, E6-E10	1.5	42
90	Low density lipoprotein oxidation, antioxidants, and atherosclerosis. <i>Current Opinion in Cardiology</i> , 2000 , 15, 355-63	2.1	65
89	Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. <i>Gene Therapy</i> , 2000 , 7, 1795-801	4	18
88	Oxidized lipoproteins and endothelium. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000 , 38, 155-60	5.9	14
87	Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase: implications for HDL function. <i>Journal of Lipid Research</i> , 2000 , 41, 975-984	6.3	23
86	The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group. <i>Acta Diabetologica</i> , 1999 , 36, 27-33	3.9	12
85	Antioxidants and coronary artery disease. <i>Current Atherosclerosis Reports</i> , 1999 , 1, 221-9	6	4
84	Oxysterols from oxidized LDL are cytotoxic but fail to induce hsp70 expression in endothelial cells. <i>FEBS Letters</i> , 1999 , 462, 113-6	3.8	9
83	NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. <i>Atherosclerosis</i> , 1999 , 145, 87-95	3.1	17
82	A successful dietary treatment fails to normalize plasma triglyceride postprandial response in type IV patients. <i>Atherosclerosis</i> , 1999 , 146, 19-23	3.1	5
81	Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. <i>Transplantation</i> , 1999 , 68, 1211	1.8	3
80	Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. <i>British Journal of Pharmacology</i> , 1998 , 125, 1471-6	8.6	25

79	Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. <i>Atherosclerosis</i> , 1998 , 137, 71-6	3.1	25
78	Hypobetalipoproteinemia associated with apo B-48.4, a truncated protein only 14 amino acids longer than apo B-48. <i>Atherosclerosis</i> , 1998 , 137, 125-31	3.1	7
77	Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits. <i>Atherosclerosis</i> , 1998 , 141, 45-51	3.1	18
76	Antioxidants and coronary artery disease. <i>Current Opinion in Lipidology</i> , 1998 , 9, 541-9	4.4	18
75	Antioxidant effect of flavonoids. <i>Angiology</i> , 1997 , 48, 39-44	2.1	71
74	Decreased intracellular degradation and increased secretion of apo B-100 in Hep G2 cells after inhibition of cholesteryl ester synthesis. <i>Atherosclerosis</i> , 1997 , 130, 143-52	3.1	17
73	Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 231, 437-41	3.4	27
72	A new fluorometric method for measuring the action of C apolipoproteins on milk lipoprotein lipase. <i>Clinica Chimica Acta</i> , 1997 , 264, 75-90	6.2	3
71	Stress proteins and atherosclerosis. <i>Atherosclerosis</i> , 1996 , 127, 147-54	3.1	36
70	Effect of the apolipoprotein C-II/C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. <i>Atherosclerosis</i> , 1996 , 127, 205-12	3.1	17
69	Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. <i>British Journal of Pharmacology</i> , 1996 , 118, 215-9	8.6	21
68	Human endothelial cells exposed to oxidized LDL express hsp70 only when proliferating. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996 , 16, 1104-11	9.4	25
67	Oxidized Ldl Trigger the Expression of Hsp70 in Cultured Endothelial Cells. <i>Medical Science Symposia Series</i> , 1996 , 603-612		
66	Oxidized LDL induce hsp70 expression in human smooth muscle cells. <i>FEBS Letters</i> , 1995 , 372, 1-5	3.8	32
65	Pharmacology of competitive inhibitors of HMG-CoA reductase. <i>Pharmacological Research</i> , 1995 , 31, 9-27	10.2	194
64	Fibrates: Modes of Action. <i>Medical Science Symposia Series</i> , 1995 , 295-306		
63	Oxidized-LDL induce the expression of heat shock protein 70 in human endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 200, 389-94	3.4	55
62	A new case of apo C-II deficiency with a nonsense mutation in the apo C-II gene. <i>Clinica Chimica Acta</i> , 1994 , 224, 111-8	6.2	6

61	Protection of low-density lipoprotein from oxidation by 3,4-dihydroxyphenylethanol. <i>Lancet, The</i> , 1994 , 343, 1296-7	40	34
60	Unique epitope of apolipoprotein A-I expressed in pre-beta-1 high-density lipoprotein and its role in the catalyzed efflux of cellular cholesterol. <i>Biochemistry</i> , 1994 , 33, 6981-5	3.2	84
59	Reduction of Lp(a) plasma levels by bezafibrate. <i>Atherosclerosis</i> , 1993 , 100, 127-8	3.1	20
58	Immunoreactivity of apo B towards monoclonal antibodies that inhibit the LDL-receptor interaction: effects of LDL oxidation. <i>Atherosclerosis</i> , 1993 , 101, 37-41	3.1	6
57	SIM 6080, a new calcium antagonist, reduces aortic atherosclerosis in cholesterol-fed rabbits. <i>Pharmacological Research</i> , 1993 , 28, 219-27	10.2	6
56	Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. <i>Journal of Clinical Investigation</i> , 1993 , 91, 677-83	15.9	72
55	Defective Catabolism of Oxidized LDL by J774 Murine Macrophages. <i>Medical Science Symposia Series</i> , 1993 , 427-439		
54	Causes Underlying the Reduced Response to Simvastatin Treatment in Hypercholesterolemic Patients 1993 , 207-229		
53	Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100. <i>Atherosclerosis</i> , 1992 , 93, 95-103	3.1	25
52	Plasma lipoproteins and cholesterol metabolism in Yoshida rats: an animal model of spontaneous hyperlipemia. <i>Life Sciences</i> , 1992 , 50, 1913-24	6.8	19
51	Mode of action of fibrates. <i>Pharmacological Research</i> , 1992 , 26, 331-40	10.2	21
50	Characterization of a family with moderate hypercholesterolemia and binding defective low density lipoprotein. <i>European Journal of Epidemiology</i> , 1992 , 8 Suppl 1, 26-32	12.1	
49	Evidence for the presence of 7-hydroperoxycholest-5-en-3 beta-ol in oxidized human LDL. <i>Chemistry and Physics of Lipids</i> , 1992 , 62, 209-14	3.7	48
48	Monoclonal antibodies to human low density lipoprotein identify distinct areas on apolipoprotein B-100 relevant to the low density lipoprotein-receptor interaction.. <i>Journal of Lipid Research</i> , 1992 , 33, 1111-1121	6.3	17
47	Defective catabolism of oxidized LDL by J774 murine macrophages.. <i>Journal of Lipid Research</i> , 1992 , 33, 819-829	6.3	45
46	Familial defective apo B-100, characterization of an Italian family. <i>European Journal of Clinical Investigation</i> , 1991 , 21, 389-97	4.6	19
45	Poor response to simvastatin in familial defective apo-B-100. <i>Lancet, The</i> , 1991 , 337, 305	40	14
44	Reduction of LDL production rate in ileal bypassed rabbits treated with lovastatin. <i>Pharmacological Research</i> , 1991 , 23, 129-37	10.2	1

43	Cholesterol stimulation of HDL binding to human endothelial cells EAhy 926 and skin fibroblasts: evidence for a mechanism independent of cellular metabolism. <i>Lipids and Lipid Metabolism</i> , 1991 , 1083, 94-100		14
42	Abnormalities of Apolipoprotein B Metabolism in the Lipid Clinic 1991 , 79-89		
41	Lecithin cholesterol acyl transferase deficiency: molecular analysis of a mutated allele. <i>Human Genetics</i> , 1990 , 85, 195-9	6.3	52
40	Oxidized LDL increase free cholesterol and fail to stimulate cholesterol esterification in murine macrophages. <i>Biochemical and Biophysical Research Communications</i> , 1990 , 171, 123-31	3.4	44
39	Immunochemical characterization of six monoclonal antibodies to human apolipoprotein A-I: epitope mapping and expression.. <i>Journal of Lipid Research</i> , 1990 , 31, 375-384	6.3	15
38	Effects of calcium antagonists on lipids and atherosclerosis. <i>American Journal of Cardiology</i> , 1989 , 64, 1291-1331; discussion 1331-1341	3	43
37	Binding-defective low-density lipoprotein in family with hypercholesterolaemia. <i>Lancet, The</i> , 1989 , 1, 623	4.0	14
36	Effects of coffee on plasma lipids, lipoproteins and apolipoproteins. <i>Pharmacological Research</i> , 1989 , 21, 27-38	10.2	6
35	Effect of bezafibrate on plasma lipid in a strain of genetically hypercholesterolemic RICO rats. <i>Pharmacological Research</i> , 1989 , 21 Suppl 1, 109-10	10.2	2
34	Plasma lipoproteins and cholesterol metabolism in spontaneously hyperlipemic rats. <i>Atherosclerosis</i> , 1989 , 76, 163-71	3.1	11
33	Assimilation of LDL by experimental tumours in mice. <i>Lipids and Lipid Metabolism</i> , 1989 , 1003, 301-6		36
32	Monoclonal antibody 5A binds apolipoprotein B-48 and inhibits the low density lipoprotein-receptor interaction. <i>Biochemical and Biophysical Research Communications</i> , 1989 , 162, 908-134	3.4	4
31	The low density lipoprotein receptor: structure, function and pharmacological modulation 1989 , 43, 187-219		10
30	Evaluation of apolipoproteins A-I and B as markers of angiographically assessed coronary artery disease. <i>Research in Clinic and Laboratory</i> , 1988 , 18, 319-28		6
29	Progesterone modulates the expression of HDL binding sites in human skin fibroblasts. <i>Atherosclerosis</i> , 1988 , 74, 107-13	3.1	6
28	The Antiatherosclerotic Effect of Anipamil in Cholesterol-Fed Rabbits. <i>Annals of the New York Academy of Sciences</i> , 1988 , 522, 519-521	6.5	22
27	A study of the structure of the gene for lecithin: cholesterol acyltransferase in four unrelated individuals with familial lecithin: cholesterol acyltransferase deficiency. <i>Clinical Science</i> , 1988 , 74, 91-6	6.5	14
26	Activation of lipoprotein lipase by apolipoprotein C-II is modulated by the COOH terminal region of apolipoprotein C-III. <i>Chemistry and Physics of Lipids</i> , 1987 , 45, 39-47	3.7	10

25	Cholesterol feeding to rats does not modulate the expression of binding sites for HDL on liver membranes. <i>Experientia</i> , 1986 , 42, 1155-7		3
24	Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. <i>Atherosclerosis</i> , 1986 , 59, 329-33	3.1	63
23	Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia. <i>Journal of Clinical Investigation</i> , 1986 , 78, 940-6	15.9	25
22	Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease). <i>European Journal of Clinical Investigation</i> , 1984 , 14, 49-54	4.6	26
21	Effects of insulin deficiency on the catabolism of plasma lipoproteins and on the expression of hepatic lipoprotein receptors in rats. <i>Pharmacological Research Communications</i> , 1984 , 16, 539-48		5
20	In vivo assimilation of low density lipoproteins by a fibrosarcoma tumour line in mice. <i>Cancer Letters</i> , 1984 , 25, 203-8	9.9	59
19	beta-Adrenergic receptors in brain microvessels of diabetic rats. <i>Life Sciences</i> , 1984 , 34, 1095-100	6.8	24
18	Effects of probucol on the in vivo plasma clearance of human low density lipoproteins in rabbits and on the expression of lipoprotein receptors in vitro. <i>Atherosclerosis</i> , 1984 , 52, 309-16	3.1	8
17	Comparative in vitro study of the pro-apolipoprotein A-I to apolipoprotein A-I converting activity between normal and Tangier plasma. <i>Journal of Clinical Investigation</i> , 1984 , 74, 1098-103	15.9	12
16	A new case of familial LCAT deficiency. <i>Acta Medica Scandinavica</i> , 1983 , 214, 173-6		14
15	Effect of partial ileal bypass on plasma clearance and binding of lipoproteins to liver membranes in the rabbit. <i>Atherosclerosis</i> , 1983 , 46, 269-73	3.1	11
14	Plasma lipids, lipoproteins and apoproteins in a case of apo C-II deficiency. <i>Clinica Chimica Acta</i> , 1983 , 130, 317-27	6.2	35
13	Experimental studies on the hypolipidemic activity of chloridarol. <i>Pharmacological Research Communications</i> , 1983 , 15, 201-15		7
12	Apolipoprotein C-II and lipoprotein lipase activity. <i>Research in Clinic and Laboratory</i> , 1982 , 12, 35-40		6
11	Formation of high density lipoprotein-like particles from chylomicrons. <i>Research in Clinic and Laboratory</i> , 1982 , 12, 51-62		
10	Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs. <i>Atherosclerosis</i> , 1981 , 40, 245-55	3.1	6
9	Abnormal suppression of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by hypertriglyceridemic very low density lipoprotein subclasses. <i>Lipids</i> , 1980 , 15, 456-63	1.6	42
8	The distribution of apo C-II and apo C-III in very low density lipoproteins of normal and type IV subjects. <i>Atherosclerosis</i> , 1980 , 35, 419-24	3.1	32

7	Activation of lipoprotein lipase by synthetic fragments of apolipoprotein C-II. <i>Annals of the New York Academy of Sciences</i> , 1980 , 348, 213-23	6.5	51
6	Activation of Lipoprotein Lipase by Synthetic Fragments of ApoC-II 1980 , 397-400		
5	Glycosaminoglycans and lipoprotein metabolism: an overview. <i>Pharmacological Research Communications</i> , 1979 , 11, 571-83		7
4	Lipolysis of ApoC-II deficient very low density lipoproteins: enhancement of lipoprotein lipase action by synthetic fragments of apoC-II. <i>Biochemical and Biophysical Research Communications</i> , 1979 , 89, 951-7	3.4	65
3	Suppression of 3-hydroxy-3-methylglutaryl-CoA reductase by low density lipoproteins produced in vitro by lipoprotein lipase action on nonsuppressive very low density lipoproteins.. <i>Journal of Biological Chemistry</i> , 1979 , 254, 1007-1009	5.4	29
2	Metaformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits. <i>Atherosclerosis</i> , 1977 , 26, 79-89	3.1	35
1	Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. Part 2. Metabolism of very low density lipoproteins in rabbits. <i>Atherosclerosis</i> , 1976 , 23, 85-96	3.1	34